Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Research & Development (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Research & Development for 5 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 57.6% to $11.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.1 million through Dec 2025, down 27.65% year-over-year, with the annual reading at $61.1 million for FY2025, 27.65% down from the prior year.
  • Research & Development for Q4 2025 was $11.3 million at Lexicon Pharmaceuticals, down from $18.8 million in the prior quarter.
  • The five-year high for Research & Development was $26.7 million in Q4 2024, with the low at $11.3 million in Q4 2025.
  • Average Research & Development over 3 years is $17.0 million, with a median of $15.5 million recorded in 2025.
  • The sharpest move saw Research & Development soared 80.77% in 2024, then tumbled 57.6% in 2025.
  • Over 3 years, Research & Development stood at $14.8 million in 2023, then skyrocketed by 80.77% to $26.7 million in 2024, then crashed by 57.6% to $11.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $11.3 million, $18.8 million, and $15.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.